Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jolanta Grembecka
University of Michigan at Ann Arbor, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kura Oncology
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
See attachment
Regulation and function of HOX genes in Ewing sarcoma pathogenesis
Project Narrative Genes that are essential for normal embryonic and post-natal development of organs and tissues are frequently hijacked in disease, in particular in the context of pediatric cancers. We have discovered that HOXD13, a gene that is normally expressed only in early limb development, is aberrantly activated in Ewing sarcoma, a bone and soft tissue tumor that peaks in adolescence. In this proposal we investigate the mechanistic basis of HOXD13 activation in Ewing sarcoma and define the downstream targets of HOXD13 that contribute to tumor growth and progression. In addition, we will test whether targeting HOXD13 using epigenetic drug therapy presents a novel therapeutic opportunity for Ewing sarcoma patients.
Filed on February 11, 2019.
Tell us what you know about Jolanta Grembecka's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Jolanta Grembecka”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $0 - $4,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $20,000 - $39,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $0 - $4,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $100,000 - $149,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $20,000 - $39,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $40,000 - $59,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $40,000 - $59,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $20,000 - $39,999 |
| Jolanta Grembecka | University of Michigan at Ann Arbor | Conflict of Interest | Kura Oncology | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.